West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

382.92 0.10 −0.03%
Market cap
$27.0B
P/E
48.7×
Fwd P/E
37.3×
Dividend yield
0.23%
F-score
8/9
Altman Z
13.89
Beneish M
−2.79
Dividend safety
100/100

West Pharmaceutical Services, Inc. (WST) Total debt

Alert me on Total debt

West Pharmaceutical Services, Inc.'s total debt at the end of fiscal 2025 was $202.8M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $202.9M. Over the past ten years it has ranged from $72.8M (fiscal 2023) to $255.0M (fiscal 2019); the current reading is higher than 45% of that period. West Pharmaceutical Services, Inc. ranks 19th of 54 Medical Instruments & Supplies companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2025 $202.8M 0.10%
FY2024 $202.6M 178.30%
FY2023 $72.8M (64.78%)
FY2022 $206.7M (1.01%)
FY2021 $208.8M (17.44%)
FY2020 $252.9M (0.82%)
FY2019 $255.0M 30.10%
FY2018 $196.0M (0.51%)
FY2017 $197.0M (12.91%)
FY2016 $226.2M (1.18%)

Quarterly newest first

Period Total debt Change
Jun 2026 $202.9M 0.05%
Mar 2026 $202.8M 0.00%
Dec 2025 $202.8M 0.05%
Sep 2025 $202.7M 0.05%
42 more quarters

Against its own ten years

Low $72.8M High $255.0M
Ten-year median $206.7M
Current reading's percentile 45

Total debt against peers

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on WST